Experimental Agent Reduces Breast Cancer Metastasis to Bone
For More Information or to Request a Photo from this News Release, Contact:
BOSTON (November 3, 2009, 1:00 p.m. ET) — Researchers have reduced breast cancer metastasis to bone using an experimental agent to inhibit ROCK, a protein that was found to be over-expressed in metastatic breast cancer. In a study in mice, the team of researchers from Tufts University School of Medicine, the Sackler School of Graduate Biomedical Sciences at Tufts, and Tufts Medical Center report that inhibiting ROCK, or Rho-associated kinase, in the earliest stages of breast cancer decreased metastatic tumor mass in bone by 77 percent and overall frequency of metastasis by 36 percent. The results suggest that ROCK may be a target for new drug therapies to reduce breast cancer metastasis.
“While the primary tumor causes significant illness and requires treatment, metastasis accounts for over 90 percent of breast cancer-related deaths. There are no treatments to eradicate metastasis. Establishing ROCK’s role in the spread of breast cancer and identifying agents to inhibit ROCK brings us one step closer to an approach that might reduce metastasis in the future,” said senior author Michael Rosenblatt, MD, professor of physiology and medicine at Tufts University School of Medicine and member of the cellular and molecular physiology program faculty at the Sackler School of Graduate Biomedical Sciences at Tufts. Rosenblatt is also dean of Tufts University School of Medicine.
“We also found that using shRNA – short hairpin RNA – to knock down ROCK expression slowed metastasis. In order for cancer cells to migrate, an extensive transportation apparatus is required. ROCK directs the formation of this apparatus, but use of the ROCK inhibitor as well as shRNA rendered the cells’ transportation mechanism ineffective, significantly reducing breast cancer metastasis to bone,” said first author Sijin Liu, PhD, research instructor and member of the Rosenblatt Laboratory at Tufts.
“This study also revealed that a specific microRNA cluster, 17 through 92, is associated with ROCK expression and breast cancer metastasis. The microRNA cluster responded to ROCK inhibition, which provides insight into the mechanism driving metastasis and is a finding that will be of particular interest to researchers focused on the role of microRNAs in gene expression,” continued Liu.
Rosenblatt, Liu, and colleagues used luminescent imaging to observe ROCK’s effect on breast cancer metastasis. The researchers found that inserting high levels of ROCK in non-metastatic cancer cells caused the cells to metastasize to several secondary sites, while cells with no ROCK exposure remained localized. The researchers then used an experimental agent (Y27632) or shRNA to reduce ROCK activity in seven mice with metastatic tumors, finding a significant decrease in metastasis to bone compared to six untreated mice.
Breast cancer is the second leading fatal cancer in women, and affects just under one in eight women in the United States. Bone is the most common site of breast cancer metastasis, affected three times more often than the lungs or liver.
The study, published online in advance of print, will appear in the November 15 issue of Cancer Research. The results were also presented at the Frontiers in Basic Cancer Research conference, held by the American Association for Cancer Research in October. The study is supported by a grant from the Susan G. Komen Breast Cancer Foundation.
Coauthors include Robert H. Goldstein, a student in the MD/PhD program at Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences; and Ellen M. Scepansky, MD, hematology and oncology fellow at Tufts Medical Center and clinical instructor in the department of medicine at Tufts University School of Medicine.
Liu S, Goldstein RH, Scepansky EM, and Rosenblatt M. Cancer Research. 2009. (November 15); 69 (22). “Inhibition of Rho-associated kinase signaling prevents breast cancer metastasis to human bone.” Published online November 3, 2009, doi:10.1158/0008-5472.CAN-09-1541
About Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences
Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts University are international leaders in innovative medical education and advanced research. The School of Medicine and the Sackler School are renowned for excellence in education in general medicine, special combined degree programs in business, health management, public health, bioengineering and international relations, as well as basic and clinical research at the cellular and molecular level. Ranked among the top in the nation, the School of Medicine is affiliated with six major teaching hospitals and more than 30 health care facilities. The Sackler School undertakes research that is consistently rated among the highest in the nation for its effect on the advancement of medical science.